Xeris Biopharma Holdings (XERS) Shares Outstanding (Diluted Average) (2021 - 2026)

Xeris Biopharma Holdings has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $177.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 16.52% year-over-year to $177.6 million; the trailing twelve-month figure through Mar 2026 stood at $177.6 million (up 16.52% YoY), and the FY2025 full-year result was $172.7 million, up 17.69% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $177.6 million, up from $172.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $177.6 million in Q1 2026, with the low at $135.0 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $147.4 million across 5 years, with a median of $140.5 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) jumped 120.48% — and 2023, when it advanced 1.45%.
• Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) stood at $135.6 million in 2022, then gained by 1.51% to $137.7 million in 2023, then advanced by 6.61% to $146.8 million in 2024, then gained by 17.69% to $172.7 million in 2025, then advanced by 2.83% to $177.6 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $177.6 million (Q1 2026), $172.7 million (Q4 2025), and $177.6 million (Q3 2025), per Business Quant data.